Approval · Notice of Compliance 28898 · 2022
RYMTI: Notice of Compliance 28898
Issued August 31, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28898
- Date
- August 31, 2022
- Company
- Lupin Pharma Canada LimitedLongueuil, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Canadian reference product
- ENBREL
Products in this notice
Medicinal ingredients
- ETANERCEPT 25 MG per 0.5ML
- ETANERCEPT 50 MG per ML